98%
921
2 minutes
20
Background: While robotic assisted technology has advanced in cardiovascular interventions, neurovascular applications still lack a robotic system. To assess the safety and efficacy of novel robotic systems designed for cerebral angiography, we conducted a multicenter, randomized controlled non-inferiority trial.
Methods: 130 patients were recruited who received cerebral angiography in four centers. After identifying the target vessels, patients were randomly allocated to an experimental group for robotic procedures and a control group for manual procedures in a 1:1 ratio. Clinical success rate, technical success rate, overall surgery time, pre-puncture set-up time, puncture-to-unsheathed time, mean catheterization time per target vessel, X-ray fluoroscopy time, and primary operator's radiation dose were compared. The safety endpoints were incidence of perioperative vascular injuries, any adverse events, and device malfunctions.
Results: 64 patients were assigned to the experimental group and 66 to the control group. Both groups achieved 100% clinical success and a 100% technical success. Significantly, the primary operator's radiation dose in the robotic group was lower than that in the manual group (1.67±3.49 μSv vs 43.63±38.95 μSv, P<0.001). The puncture-to-unsheathed time (P=0.882), mean catheterization time per target vessel (P=0.247), and fluoroscopy time (P=0.701) were comparable. The pre-puncture set-up time in the robotic group was longer (P<0.001), attributed to prolonged robotic instrument set-up. No robot related adverse events were observed.
Conclusion: The trial showed that the robotic system was safe and effective for assisting cerebral angiography, notably reducing primary operators' radiation exposure.
Trial Registration Number: ClinicalTrials.gov NCT05778214.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/jnis-2025-023412 | DOI Listing |
Stroke
September 2025
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. (V.Y., B.C.V.C., L.C., L.O., M.W.P.).
Background: To assess the efficacy and safety of tenecteplase in patients presenting within 24 hours of symptom onset with a large vessel occlusion and target mismatch on perfusion computed tomography.
Methods: ETERNAL-LVO was a prospective, randomized, open-label, blinded end point, phase 3, superiority trial where adult participants with a large vessel occlusion, presenting within 24 hours of onset with salvageable tissue on computed tomography perfusion, were randomized to tenecteplase 0.25 mg/kg or standard care across 11 primary and comprehensive stroke centers in Australia.
Circulation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDFRetin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.
Int J Gen Med
September 2025
Department of Pediatric, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, Jilin, 130000, People's Republic of China.
Background: Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory infection in children, current treatments are limited by resistance and side effects. This study aims to evaluate the clinical efficacy and safety of combining Qingke Mixture with azithromycin for treating MPP in children.
Methods: This prospective, randomized, double-blind, controlled trial included 92 children diagnosed with MPP.
Mol Ther Methods Clin Dev
June 2025
Precision Safety, Pharma Product Development, Roche Innovation Center Basel, CH-4070 Basel, Switzerland.
Adeno-associated virus (AAV) vectors are widely used in gene therapy, particularly for liver-targeted treatments. However, predicting human-specific outcomes, such as transduction efficiency and hepatotoxicity, remains challenging. Reliable models are urgently needed to bridge the gap between preclinical studies and clinical applications.
View Article and Find Full Text PDF